We are the combination of four hospitals: the General Hospital, the Children’s Hospital, the Women’s Hospital and the Traumatology, Rehabilitation and Burns Hospital. We are part of the Vall d’Hebron Barcelona Hospital Campus: a world-leading health park where healthcare plays a crucial role.
Patients are the centre and the core of our system. We are professionals committed to quality care and our organizational structure breaks down the traditional boundaries between departments and professional groups, with an exclusive model of knowledge areas.
Would you like to know what your stay at Vall d'Hebron will be like? Here you will find all the information.
The commitment of Vall d'Hebron University Hospital to innovation allows us to be at the forefront of medicine, providing first class care adapted to the changing needs of each patient.
The ductus arteriosus is a blood vessel connecting the aorta to the pulmonary artery. It spontaneously closes after birth in the majority of infants born at full term, and this is essential in order for the baby to survive. However, in premature babies, closure of the ductus arteriosus is often delayed until more than a week after being born.
The most common clinical sign is the onset of a murmur under the left collar bone. Patent ductus arteriosus may be accompanied by a high heart rate and rapid breathing and also increased pulmonary flow. This increase produces congestion which prevents development of the lungs in premature babies.
It principally affects premature babies. Patent ductus arteriosus affects 30% of premature babies weighing under 1500g.
Patent ductus arteriosus is detected via echocardiogram.
When the patent ductus arteriosus affects the new-born’s health, initial treatment is medical and pharmacological.
Indometacin is the standard treatment for closing the ductus arteriosus with medication. Ibuprofen can also be used as this anti-inflammatory gives good results in these cases.
The usual treatment would be closure via catheterization. This means inserting a catheter into the ductus arteriosus to close it. This type of closure would normally be used for babies with ductus arteriosus under 3 mm diameter and who are of a suitable weight.
Surgical treatment is reserved for patients where pharmacological treatment has failed, or where it is not advisable, and for cases where catheterization is not recommended.
Prognosis is excellent both for closure through catheterization and surgery. The recanalization rate of patent ductus arteriosus is estimated at 0-3 %.
The acceptance of these terms implies that you give your consent to the processing of your personal data for the provision of the services you request through this portal and, if applicable, to carry out the necessary procedures with the administrations or public entities involved in the processing. You may exercise the mentioned rights by writing to web@vallhebron.cat, clearly indicating in the subject line “Exercise of LOPD rights”. Responsible entity: Vall d’Hebron University Hospital (Catalan Institute of Health). Purpose: Subscription to the Vall d’Hebron Barcelona Hospital Campus newsletter, where you will receive news, activities, and relevant information. Legal basis: Consent of the data subject. Data sharing: If applicable, with VHIR. No other data transfers are foreseen. No international transfer of personal data is foreseen. Rights: Access, rectification, deletion, and data portability, as well as restriction and objection to its processing. The user may revoke their consent at any time. Source: The data subject. Additional information: Additional information can be found at https://hospital.vallhebron.com/es/politica-de-proteccion-de-datos.